肠促胰素类疗法治疗酒精使用障碍的临床证据综述
本文综述胰高血糖素样肽-1受体激动剂(GLP-1RA)治疗酒精使用障碍(AUD)的现有临床证据。迄今仅3项随机对照试验显示GLP-1RA可降低酒精线索相关脑反应性与饮酒量,尤其在超重或肥胖者中;观察性数据也一致提示GLP-1RA使用与饮酒减少相关。总体上GLP-1RA是有前景的新型AUD治疗策略,尚需更大规模长期随机试验验证。
要点
- 仅3项随机对照试验:GLP-1RA降低酒精线索脑反应性与饮酒量。
- 观察性及真实世界数据一致关联GLP-1RA使用与饮酒减少。
- 机制可能涉及奖赏回路、动机显著性、胃排空与代谢信号调节。
核心结论
- GLP-1RA是机制新颖且有前景的AUD治疗策略,但需更大规模长期随机试验确认。
研究设计与样本
- 叙述性综述,汇总GLP-1RA用于AUD的现有临床证据,包括随机对照试验、观察性数据与机制研究。
主要发现
- 迄今仅3项随机对照试验考察GLP-1RA治疗AUD,显示酒精线索脑反应性与饮酒量降低。
- 上述随机对照试验中效应尤其见于超重或肥胖个体。
- 大型登记研究、目标试验模拟分析及真实世界数据一致显示GLP-1RA使用与饮酒减少相关。
- 病例报告与社交媒体分析进一步支持GLP-1RA降低酒精渴求与饮酒。
- 机制证据指向奖赏回路、动机显著性、胃排空与代谢信号调节。
临床怎么用
- 现有证据支持在超重或肥胖AUD患者中关注GLP-1RA的潜在减少饮酒作用。
- 将GLP-1RA作为AUD新靶点探索时,应结合代谢与奖赏机制评估疗效。
局限性
- 随机对照试验仅3项,证据以观察性数据、病例报告与临床轶事为主。
- 尚缺乏更大规模、长期随机试验确认疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Alcohol use disorder (AUD) remains a major global health burden, but pharmacological treatment options are limited, and there is an urgent need for novel molecular targets for the treatment of AUD. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been used for more than 2 decades to treat type 2 diabetes and subsequently overweight and obesity. Unexpected effects, including reduced alcohol intake, have been reported by patients as well as by clinicians, and these (often anecdotal) reports have been supported by a growing body of data from large registry studies; target trial emulation analyses; preclinical experiments with mice, rats, and nonhuman primates; and randomized clinical trials associating the use of GLP-1RAs with reduced alcohol consumption. This convergence has sparked growing interest in GLP-1RAs as a novel therapeutic strategy for AUD. In this narrative review, we synthesize current evidence on the effects of GLP-1RAs in individuals with AUD. To date, only 3 randomized controlled trials have examined GLP-1RAs in AUD, showing reductions in alcohol cue brain reactivity and alcohol consumption, particularly among individuals with overweight or obesity. We also report on observational data, including large registry studies, target trial emulation analyses, and real-world data, which have consistently associated GLP-1RA use with reduced alcohol consumption. Case reports and social media analyses further corroborate reductions in alcohol craving and consumption. Mechanistically, emerging evidence points to modulation of reward circuitry, incentive salience, gastric emptying, and metabolic signaling. Overall, GLP-1RAs represent a promising and mechanistically novel approach to AUD treatment, warranting confirmation in larger, long-term randomized trials.
引用
- Klausen MK, Fink-Jensen A. Therapeutic Potential of Incretin-Based Therapies for Alcohol Use Disorder: A Narrative Review of Available Clinical Evidence. Biol Psychiatry. 2026. PMID: 42486217. doi:10.1016/j.biopsych.2026.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。